Kornimate/medical-research-clean huggingface dataset:
soft contact lens fitting with different sagittal height

Conditions: Myopia

Summary: to evaluate whether there is a difference in subjective and objective fit of soft lenses with different sagittal height


Eligibility criteria:
inclusion criteria: * age more than 18 years * no active eye disease * 5 soft lenses for the experiment can be successfully worn and all examinations can be completed as required exclusion criteria: * active eye disease * bcva less than 20/25 * those who are too small or tight eyelids are not suitable for wearing soft lenses
salvage cryotherapy in recurrent prostate cancer

Conditions: Recurrent Prostate Cancer

Summary: to provide a systemic, uniform and user-friendly tool for collection of data on prostate cancer salvage cryotherapy in a multicenter setting. the goal is to learn more about the short and long term efficacy and safety of this procedure. ultimately the data analysis will serve as a robust guidance instrument for improving upon the utilization of this procedure for the treatment of patients with recurrent (lrd) prostate cancer.


Eligibility criteria:
inclusion criteria: * read \& understand informed consent related to this study including consenting and hippa authorization * undergone salvage cryotherapy of the prostate for recurrent prostate cancer exclusion criteria: * patients who underwent radical prostatectomy as their primary therapy or other significant surgery (except prostatic biopsy) * patients with clinically confirmed distant metastasis (unless deemed beneficial by the treating physician) * any previous major rectal surgery * clinically significant lower urinary tract or rectal anomalies * existing urethral, rectal, or bladder fistulae

Keywords: prostate cancer recurrent prostate cancer prostate cancer recurrence radiation failure salvage cryotherapy
nippv vs.ncpap during lisa procedure

Conditions: Respiratory Distress Syndrome, Newborn

Summary: the goal of this randomized controlled study is to compare the efficacy of using nippv versus ncpap during the lisa procedure in very preterm infants. the main question it aims to answer is: • does nippv during the lisa procedure decrease the need for a second dose of surfactant or the need of mechanical ventilation during the first 72 hours of life in comparison with ncpap? infants with gestational age between 25+0 and 31+6 weeks of gestation with rds who do not require vm and treated with ncpap and fio2 \>0.30 within the first 6 hours of life who received the first dose of caffeine will be eligible for enrollment in the study participants will be randomized to receive surfactant with conventional lisa procedure, i.e. performed during ncpap, or with lisa procedure performed during nippv.


Eligibility criteria:
inclusion criteria: * -infants with gestational age between 25+0 and 31+6 gestational weeks, * -rds which does not require mv * -treatment with ncpap and fio2 \>0.30 within the first 6 hours of life, * -first dose of caffeine administered exclusion criteria: * -absence of informed consent, * -major congenital malformations, * -hydrops fetalis, * -chromosomal diseases, * -previous treatment with surfactant, * -cardiorespiratory instability requiring treatment with vasoactive drugs, * -pneumothorax, * -death within 72 hours of life.

Keywords: surfactant lisa procedure preterm infant
free flaps : should we propose them to the elderly ?

Conditions: Head and Neck Cancer

Summary: the objective was to evaluate perioperative morbidity after head and neck microsurgical reconstruction.

the objective was to evaluate perioperative morbidity after head and neck microsurgical reconstruction. a retrospective chart review of all patients undergoing head and neck free flap reconstruction was conducted and the overall hospital length of stay and the incidence of perioperative medical and surgical complications were assessed.

Eligibility criteria:
inclusion criteria: * head and neck cancer * microsurgical free flap reconstruction * 18 years of age or older exclusion criteria: -
pivotal trial of a novel paclitaxel-coated percutaneous angioplasty balloon

Conditions: Peripheral Arterial Disease

Summary: this study is designed to evaluate the safety and efficacy of a paclitaxel-coated percutaneous transluminal angioplasty (pta) catheter in the treatment of patients with peripheral arterial disease.

the illumenate pivotal study is a prospective, randomized, multi-center, single-blind study which will include up to 360 subjects in approximately forty-five (45) sites across the united states to evaluate the cvi paclitaxel-coated pta catheter compared to the bare percutaneous transluminal angioplasty balloon catheter (bare balloon catheter) for the treatment of de-novo or post-pta occluded/stenotic or reoccluded/restenotic (except for in-stent) sfa and/or popliteal arteries.

Eligibility criteria:
inclusion criteria: * subjects with symptomatic leg ischemia, requiring treatment of the superficial femoral artery (sfa) or popliteal artery. exclusion criteria: * known intolerance to study medications, paclitaxel or contrast agents that in the opinion of the investigator cannot be adequately pre-treated
detection and metabolic characterization in dopa pet/ct of brain metastases

Conditions: Brain Metastases; MRI

Summary: about 20 to 30% of patients treated for cancer will have brain metastases. these brain metastases are found more frequently in patients with lung cancer, breast cancer or melanoma. the prognosis of these patients is unfavorable but prolonged survival can be obtained with the local and systemic treatments currently available. brain mri is the gold standard for evaluating brain metastases but has limitations in therapeutic evaluation, partially offset by pet imaging of amino acid metabolism. our work aims to compare the performance of pet-dopa with standard mri for the detection of brain metastases (≥ 5mm) in lung cancer, breast cancer and melanoma; and to characterize these lesions using dynamic acquisitions obtained with a digital pet camera with high spatial resolution. having better knowledge of the metabolic characteristics of newly discovered brain metastases, the objective of subsequent studies will be to better assess the per- or post-therapeutic efficacy of radiotherapy and the various systemic therapies available (chemotherapy, targeted therapy, immunotherapy).


Eligibility criteria:
inclusion criteria: * primitive cancer (brest cancer, lung cancer, melanoma) proven histologically * presence of brain metastasis visualized on mri, of which at least one measures 5 mm * age \> 18 years * patient has valid health insurance * written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations exclusion criteria: * history of irradiation cerebral * history of brain surgery for brain metastasis or glial tumor * systemic therapy (chemotherapy, targeted therapy, immunotherapy) modified in the 6 weeks preceding the realization of dopa pet/ct, * new anti-tumor treatment started between the discovery of brain metastases and the performance of dopa pet/ct * other concomitant cancer, or history of cancer in the 5 years preceding the performance of dopa pet/ct * pregnant or lactating females * persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian. disorder precluding understanding of trial information or informed consent.

Keywords: breast cancer lung cancer melanoma dopa pet/ct
bias source of signal in scout ds

Conditions: Type 2 Diabetes

Summary: the primary objective is to identify device characteristics, components or subsystems that manifest as screening score bias in scout ds.

in the process of calibrating multiple scout ds units, consistent inter-device score differences were found. these differences could create a bias in the measurement of diabetes risk scores (drs) in human subjects. this study is intended to examine two of the various subsystems of the scout ds to determine whether either of them might be capable of introducing bias into the measurements, with the ultimate aim of eliminating inter-device measurement variation. the testing of human subjects in this trial is necessary to determine whether variability in the performance of these device subsystems actually affect drs scores in a real world setting. the trial will be a prospective, single site, investigational trial. the trial will utilize four scout ds devices. subjects will report to the investigative site for multiple visits. the number of visits will vary between three to seven visits.

Eligibility criteria:
inclusion criteria: * males and/ or females greater than or equal to 18 years of age exclusion criteria: * have received investigational treatments in the past 14 days * have psychosocial issues that interfere with an ability to follow study procedures * are known to be pregnant * have scars, tattoos, rashes or other disruption/discoloration on the left volar forearm. * have been treated in the past month with oral steroid therapy or topical steroids applied to the left forearm. inhaled steroid therapy is not a basis for exclusion * are receiving medications that fluoresce (a list of excluded medications is located in appendix h) * are known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)

Keywords: screening for type 2 diabetes
stem cell therapy in muscular dystrophy

Conditions: Muscular Dystrophy

Summary: the purpose of this study was to analyze the effect of autologous bone marrow mononuclear cells in muscular dystrophy.


Eligibility criteria:
inclusion criteria: * age group of 6 months and above * muscular dystrophy diagnosed on the basis of clinical presentation exclusion criteria: * presence of respiratory distress * presence of acute infections such as human immunodeficient virus/hepatitis b virus/hepatitis c virus * malignancies * acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction \< 30% * pregnancy or breastfeeding

Keywords: muscular dystrophy autologous mononuclear cell therapy stem cell
pca loading time before knee prosthetic joint infection revision

Conditions: Prosthesis-Related Infections

Summary: proof of principle pilot study of the effect of dietary nutritional loading of protocatechunic acid (pca) on the health and welfare of individuals with prosthetic joint infection (pji), as measured by standard biomarkers

our purpose in the pre-surgery serial aspiration study is to determine the optimal pca loading time duration for those with knee pji with planned single or two stage revision.our hypothesis, related to changes in structure and function as a result of pca administration is that dietary nutritional loading of this nutraceutical pca via the oral route will benefit the health and welfare of such a subject and alter the function and or structure of the human body having a pji, as measured by improvemen in a pain biomarker, and one or more laboratory-based biomarkers.

Eligibility criteria:
inclusion criteria: * more than 3 weeks after total knee arthroplasty * one or more symptoms of injection, including redness, swelling, pain, increasing range of motion loss, fever, nausea, and loss of appetite. * wbc count of aspiration \>50,0000 cells per μl exclusion criteria: - not willing to undergo blood draw and joint needle aspiration weekly up to 4 weeks
perhexiline therapy in heart failure with preserved ejection fraction syndrome

Conditions: Diastolic Heart Failure

Summary: up to half of all patients with clinical features of heart failure are found to have normal heart pumping function. recently the investigators have shown that a drug called perhexiline markedly improved exercise capacity and symptoms in patients with heart failure associated with impaired cardiac pump function. in this proposal the investigators will assess whether perhexiline has beneficial effects in patients with heart failure and a normal heart pumping function.

up to 50% of patients with symptoms of heart failure have a preserved left ventricular ejection fraction (hfpef syndrome). current therapy for systolic heart failure is targeted at inducing vasodilation and counteracting neuro-endocrine activation. there is a lack of a corresponding evidence base for the treatment of hepef. we have previously shown that perhexiline, an agent that increases the efficiency of energy production by shifting substrate utilization from free fatty acids towards glucose, was highly effective in improving exercise capacity, symptoms and cardiac function in patients with systolic heart failure. we have also recently shown that energy deficiency plays a major role in the pathophysiology of hfpef. in this proposal we therefore aim to investigate the effectiveness of perhexiline in 70 hfpef patients, in a 3 month randomised, double-blind, controlled trial. an interim analysis is planned after 20 patients.

Eligibility criteria:
inclusion criteria: * hfpef will be defined as: * clinical features consistent with heart failure * lvef ≥ 50%, with no evidence of significant valvular disease * no hypertrophic cardiomyopathy, and no evidence of pericardial constriction * peak vo2 \ 1 and with a pattern of gas exchange on metabolic exercise testing indicating a cardiac cause for limitation) * patients recruited will be in sinus rhythm exclusion criteria: * bmi \>35 * objective evidence of lung disease on formal lung function testing * reversible myocardial ischaemia on contrast-enhanced myocardial stress echocardiography, and no evidence of exercise-induced mitral regurgitation (\>2+) * impaired hepatic function; known hypersensitivity to perhexiline

Keywords: diastolic dysfunction cardiac energetics perhexiline magnetic resonance spectroscopy
acute kidney injury following cardiac surgery

Conditions: Acute Kidney Injury

Summary: acute kidney injury (aki) occurs in approximately one-third of patients undergoing cardiac surgery (cs), and represents one of the most significant negative predictors of patient outcome in this population. the investigators sought to examine the risk factors associated with the development of aki and renal recovery in patients undergoing cardiac surgery at san bortolo hospital, italy 2014-2015.

acute kidney injury (aki) occurs in approximately one-third of patients undergoing cardiac surgery (cs), and represents one of the most significant negative predictors of patient outcome in this population. the investigators sought to examine the risk factors associated with the development of aki and renal recoveryin patients undergoing cardiac surgery at san bortolo hospital, italy during november 2014 - october 2015.

Eligibility criteria:
inclusion criteria: - adult cardiac surgery exclusion criteria: 1. missing baseline serum creatinine (defined as a serum creatinine value within 90 prior to surgery) or missing serum creatinine within 3 days before hospital discharge 2. stage 5 chronic kidney disease (estimated glomerular filtration rate \<15 ml/min/1.73 m2 or receipt of chronic dialysis) 3. solid organ transplant recipients
depth of anaesthesia and cognitive dysfunction

Conditions: Cognitive Dysfunction

Summary: the purpose of this study is to investigate if there is an association between the depth of anaesthesia and the presence of cognitive deterioration after surgery.


Eligibility criteria:
inclusion criteria: * age above 60 * surgery in general anesthesia * surgery \> 1 hour * asa: 1-3 exclusion criteria: * dementia * excessive use of alcohol or anxiolytics * unable to understand danish * mmse score \< 24

Keywords: postoperative cognitive dysfunction
emergence agitation after premedication in paediatric magnetic resonance imaging: a retrospective cohort study

Conditions: Autism Spectrum Disorder; Premedication; Brain Neoplasms; Brain Pathology; Growth Retardation

Summary: the aim of this study was to assess the anxiolytic and sedative effect of ozalin® / ozased® (adv6209) 0,25mg/kg in children undergoing magnetic resonance imaging (mri) under inhalational anesthesia. our hypothesis is that compared to children who do not receive any premedication, palatability of ozalin® / ozased® by allowing an easier acceptance of the drug, improves the quality of anesthesia induction and postoperative behavioral outcome improving sedation and reducing the need for inhalation anesthetic which has been recognized as the main cause of post-procedural behavioral changes, including emergence agitation.

magnetic resonance imaging is considered the primary investigative tool for evaluating a wide range of paediatric medical conditions. sedatives are often needed in this population to ensure immobilization during the acquisition of the images. midazolam has always been the most used anxiolytic-sedative drug in the pediatric population. over time, the intravenous formulation of midazolam has been used also for oral, nasal or rectal administration but those alternative routes of administration represent an off-label use. recently, in europe was licensed adv6209, a midazolam solution for oral use containing gamma-cyclodextrin (ozalin® / ozased®). the aim of this study was to assess its anxiolytic and sedative effect at a dosage of 0,25mg/kg in children undergoing magnetic resonance imaging (mri) under inhalational anesthesia. our hypothesis is that compared to children who do not receive any premedication, palatability of ozalin® / ozased® by allowing an easier acceptance of the drug, improves the quality of anesthesia induction and postoperative behavioral outcome improving sedation and reducing the need for inhalation anesthetic which has been recognized as the main cause of post-procedural behavioral changes, including emergence agitation.

Eligibility criteria:
inclusion criteria: - we included in the study 100 children (either gender), aged 1-10 years, american society of anaesthesiologists (asa) physical status 1 and 3 who, between march and december 2022, received inhalation anesthesia for brain and spinal cord mri for diagnostic investigations or postoperative and oncological follow-up exclusion criteria: * 1) a history of hypersensitivity to midazolam; 2) chronic therapy with benzodiazepines; 3) acute respiratory tract infections; 4) psychiatric and behavioural disorders; 5) asa physical status \>3.
effect of upper third molar extraction on distalization carriere motion appliance :a prospective clinical study

Conditions: Class II Malocclusion

Summary: this clinical study will be directed to compare the effect of presence or absence of third molar on distalization of the upper posterior segment by using carriere motion appliance


Eligibility criteria:
inclusion criteria: 1. angle´s class ii canine relationship, at least half-unit. 2. skeletal class i or mild class ii relationship. 3. upper second molars were fully erupted before starting distalization. 4. normal or horizontal growth pattern. 5. good oral hygiene. 6. absence of any systemic diseases exclusion criteria: previous orthodontic treatment. 2. patients who required surgery to correct skeletal discrepancies (sever skeletal class11). 3. patients with hyperdontia, hypodontia, or syndromic diseases. 4. extraction or badly destructed teeth in upper arch -
endoscopic ultrasound findings in esophageal atresia following surgical repair

Conditions: Esophageal Atresia

Summary: children with esophageal atresia who undergo surgical repair are at risk for anastomotic stricture following surgery. esophageal stricture can be treated with serial endoscopic dilation but may ultimately need surgical resection if the stricture proves refractory to therapy. several risk factors have been reported for development of recalcitrant stricture, but to date, no studies have specifically examined the relationship between anastomotic thickness and echotexture at time of initial postoperative endoscopy and treatment outcomes. other risk factors that have been implicated in the development of recalcitrant stricture include gastroesophageal reflux disease, anastomotic leak, long-gap esophageal atresia, and gestational age. moreover, it is poorly understood how esophageal layers alter and progress with repeated therapeutic dilation. the investigator hypothesize that the initial thickness and echotexture will help determine therapeutic outcome. it will also help us understand the progression of esophageal echotexture following therapeutic dilation.


Eligibility criteria:
inclusion criteria: - patients ages 0-21 years old at time of evaluation with a suspected diagnosis of esophageal stricture secondary to esophageal atresia (with or without tracheoesophageal fistula) post surgical repair exclusion criteria: * patients with pre-diagnosis of eosinophilic esophagitis * patients with pre-diagnosis of congenital esophageal stricture * patients diagnosed with esophageal stricture secondary to caustic ingestion * patient is diagnosed with an esophageal perforation at time of endoscopy
description of a cohort of covid-19 patients with a circulating anticoagulant

Conditions: SARS-COV-2

Summary: sars-cov-2 infection is responsible for a potentially severe primarily respiratory infection called covid19. a large proportion of patients, in particular in severe forms, present with thrombotic manifestations (dvt, ep, stroke, thrombosis of dialysis circuits, etc.). a significant proportion is also a carrier of circulating anticoagulant (acc or la), making it possible to suggest a diagnosis of aps. this type of autoantibody results in a spontaneous prolongation of the tca uncorrected by a control serum therefore is quickly diagnosed using standard hemostasis the objective of this study is to describe the diagnosis of thrombotic complications in covid19 patients presenting a positive lupus anticoagulant type test (la) or apl and the associated clinical and biological elements that may have favored thrombosis.


Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old) * patient taken care of in the smo pole or the nhc surgical resuscitation service or hospitalized or consultant to the hus between 01/03/2020 and 31/05/2020 * patient infected with covid-19, with a documented infection, having presented a documented thrombosis (arterial or venous), with an la or apl in the thrombosis assessment * or patient infected with covid-19, with a documented infection, without documented thrombosis (arterial or venous), with in the standard work-up an increase in tca revealing the presence of la * subject having given his agreement for the reuse of his data for the purposes of this research exclusion criteria: * subject having expressed opposition to participating in the study * subject under guardianship or guardianship * subject under safeguard of justice

Keywords: sars-cov-2 covid-19 antiphospholipid syndrome (aps) autoimmune disease antiphospholipid antibodies (apl) thrombosis